NEOK Bio Raises $75M to Develop Dual-Targeting Cancer ADCs
The biotech industry just saw a bold new entrant. NEOK Bio launched publicly with $75 million in Series A funding and a clear mission: build next-generation dual-targeting antibody-drug conjugates (ADCs)…